NCT03266601

Effect of Recombinant Human Interferon α-2b Spray on Herpangina

Effect and Safety of Recombinant Human Interferon α-2b Spray on Herpangina in Pediatric Patients

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 668 (actual)
• Sponsor: Children's Hospital of Fudan University · Academic / Other
• Sex: All
• Age: 1 Year – 7 Years
• Healthy volunteers: Not accepted

Summary

This is a multicenter, open，randomized controlled trial aiming to evaluate the effectiveness of recombinant human interferon α-2b spray compared with ribavirin treatment on pediatric patients with herpangina.

Conditions

• Herpangina

Interventions

Type	Name	Description
DRUG	Recombinant Human Interferon α-2b Spray	Recombinant human interferon α-2b spray (trade name Jeferon, specifications: 1 million U/support, 10mL/support or 2 million U/support, 20mL/support, 2-8 ℃ dark storage and transportation), 1 million U/day, used for 3 days, observed to the 4th day (until the 96th hour).
DRUG	Ribavirin	Ribavirin Spray, spray once every 4-5 hours, 1-2 times a spray, used for 3 days, observed to the 4th day(until the 96th hour ).

Timeline

• Start date: 2016-06-01
• Primary completion: 2018-11-30
• Completion: 2018-12-31
• First posted: 2017-08-30
• Last updated: 2019-03-07

Locations

1 site across 1 country: China